Symbolbild · KI-generiert
Oculis Holding AG Ordinary shares
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Oculis is a Swiss ophthalmology company developing medicines for serious eye diseases. Its pipeline focuses on therapies for diabetic macular oedema and dry eye disease, based on innovative drug delivery approaches. The company is in the clinical development stage and is listed on NASDAQ.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Oculis Holding AG Ordinary shares | OCS | NASDAQ | 656 Mio. USD |
| Achieve Life Sciences, Inc. | ACHV | NASDAQ | 659 Mio. USD |
| Allogene Therapeutics, Inc. | ALLO | NASDAQ | 649 Mio. USD |
| Enghouse Systems Limited | ENGH | TSX | 663 Mio. USD |
| BridgeBio Oncology Therapeutics, Inc. | BBOT | NASDAQ | 648 Mio. USD |
| Gyre Therapeutics, Inc. | GYRE | NASDAQ | 641 Mio. USD |
| CeriBell, Inc. | CBLL | NASDAQ | 671 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.